Boehringer Ingelheim may have been on a spending spree for licensing deals so far this year—but the German pharma has plenty ...

The number of drugs in development has fallen for the first time since the mid-1990s, according to a Citeline report. | The ...

After securing a multibillion-dollar biobucks deal with AstraZeneca and raising nearly $100 million last year, peptide drug ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...